Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cephalon, an international biopharmaceutical company, has acquired Swiss-based pharmaceutical company Mepha. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon.
Subscribe to our email newsletter
Cephalon said that the purchase price paid at closing, inclusive of certain closing adjustments, was CHF662.4m. The purchase price is also subject to further post-closing working capital and net debt adjustments.
Frank Baldino, chairman and CEO of Cephalon, said: “We are proud to include Mepha as part of the Cephalon family. This acquisition expands our presence in Europe, and we believe Mepha will contribute to our long-term growth.”
Alain Aragues, executive vice president and president of Cephalon Europe, said: “We are pleased to add Mepha’s experience and expertise, which are critical to our successful development of a balanced business mix in Europe, Middle East and Africa.
“Cephalon intends to leverage Mepha’s brand recognition as the number one generics company in Switzerland and a prominent generic pharmaceutical company in many other markets.”